CNBC: Drug pricing not discussed in White House biomedical meeting

WASHINGTON — Executives from Celgene, Regeneron and Vertex represented the drug industry Monday during a biomedical research discussion, but drug prices, long a concern of President Donald Trump, was not discussed during the two-hour meeting, reported CNBC.

"There's all kinds of elephants, and the room is crowded with them I suppose, but that one didn't get much attention," Dr. Francis Collins, director of the National Institutes of Health, told CNBC in an interview directly after the meeting.

The meeting was attended by Ivanka Trump, Jared Kushner, Health and Human Services secretary Tom Price and Vice President Mike Pence.

"The real intent here was to try to have these various participants in this amazing ecosystem of American biomedicine talk about how all these parts have to fit together in order for the discoveries to continue to roll forward, the medical advances, the cures for disease to continue to happen at a very exciting time in terms of an accelerated pace," Collins said.

To read the CNBC report, click here.